Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks according to Wall Street analysts. In a report released on August 13, Gena Wang from Barclays maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with a price target of $86.00.

BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide.

The rating update came after BioMarin Pharmaceutical Inc. reported its fiscal Q2 2025 results on August 4, with total revenues reaching $825 million, up 16% year-over-year and up 17% at constant currency year-over-year.

GAAP diluted earnings per share (EPS) for the quarter was $1.23, up 124% year-over-year, while non-GAAP diluted EPS reached $1.44, up 50% year-over-year.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.